These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 12637127)

  • 1. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease.
    Hogan TJ; Geddes R; Gonzalez ER
    Clin Ther; 2003 Jan; 25(1):285-97. PubMed ID: 12637127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
    Tashkin DP; Rennard SI; Martin P; Ramachandran S; Martin UJ; Silkoff PE; Goldman M
    Drugs; 2008; 68(14):1975-2000. PubMed ID: 18778120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formoterol: a review of its use in chronic obstructive pulmonary disease.
    Cheer SM; Scott LJ
    Am J Respir Med; 2002; 1(4):285-300. PubMed ID: 14720051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study.
    Wadbo M; Löfdahl CG; Larsson K; Skoogh BE; Tornling G; Arweström E; Bengtsson T; Ström K;
    Eur Respir J; 2002 Nov; 20(5):1138-46. PubMed ID: 12449166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
    Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
    Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.
    Rennard SI; Tashkin DP; McElhattan J; Goldman M; Ramachandran S; Martin UJ; Silkoff PE
    Drugs; 2009; 69(5):549-65. PubMed ID: 19368417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease.
    Dahl R; Greefhorst LA; Nowak D; Nonikov V; Byrne AM; Thomson MH; Till D; Della Cioppa G;
    Am J Respir Crit Care Med; 2001 Sep; 164(5):778-84. PubMed ID: 11549532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled formoterol versus ipratropium bromide in chronic obstructive pulmonary disease.
    Chhabra SK; Vijayan VK; Vasu T
    Indian J Chest Dis Allied Sci; 2006; 48(2):97-102. PubMed ID: 16696522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives.
    Mittmann N; Hernandez P; Mellström C; Brannman L; Welte T
    Pharmacoeconomics; 2011 May; 29(5):403-14. PubMed ID: 21504240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone.
    Löfdahl CG; Ericsson A; Svensson K; Andreasson E
    Pharmacoeconomics; 2005; 23(4):365-75. PubMed ID: 15853436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there any difference between effects of ipratropium bromide and formoterol on exercise capacity in moderate COPD patients?
    Akkoca Yildiz O; Onen ZP; Demir G; Eriş Gülbay B; Saryal S; Karabiyikoğlu G
    Tuberk Toraks; 2006; 54(2):105-13. PubMed ID: 16924565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
    Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
    Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease.
    Appleton S; Jones T; Poole P; Pilotto L; Adams R; Lasserson TJ; Smith B; Muhammad J
    Cochrane Database Syst Rev; 2006 Jul; 2006(3):CD006101. PubMed ID: 16856113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study.
    D'Urzo AD; De Salvo MC; Ramirez-Rivera A; Almeida J; Sichletidis L; Rapatz G; Kottakis J;
    Chest; 2001 May; 119(5):1347-56. PubMed ID: 11348938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.
    Hanania NA; Boota A; Kerwin E; Tomlinson L; Denis-Mize K
    Drugs; 2009 Jun; 69(9):1205-16. PubMed ID: 19537837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial.
    Noonan M; Rosenwasser LJ; Martin P; O'Brien CD; O'Dowd L
    Drugs; 2006; 66(17):2235-54. PubMed ID: 17137405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
    Dahl R; Chung KF; Buhl R; Magnussen H; Nonikov V; Jack D; Bleasdale P; Owen R; Higgins M; Kramer B;
    Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease.
    Oostenbrink JB; Rutten-van Mölken MP; Al MJ; Van Noord JA; Vincken W
    Eur Respir J; 2004 Feb; 23(2):241-9. PubMed ID: 14979498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
    Jarvis B; Markham A
    Drugs Aging; 2001; 18(6):441-72. PubMed ID: 11419918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.